Campbell David Alan 4

What Happened

• David Alan Campbell, President, CEO and Director of Janux Therapeutics (JANX), reported exercising stock options on July 8, 2026. The Form 4 shows an acquisition of 7,000 shares at $4.21 per share for a total of $29,470.
• The filing also includes a second derivative entry (code M) for 7,000 shares listed as disposed at $0 (derivative). The Form does not report cash proceeds for that line.

Key Details

• Transaction date: July 8, 2026.
• Primary entry: exercised options to acquire 7,000 shares at $4.21 — total cost $29,470.
• Secondary entry: 7,000 derivative units reported as disposed at $0 (no proceeds shown).
• Footnote: F1 — Immediately exercisable.
• Filing date: July 10, 2026 (appears timely relative to the July 8 transaction).
• Shares owned after transaction: Not disclosed in the provided filing.

Context

• This was an option exercise (derivative transaction). Exercising options represents a cash outlay to acquire shares (a purchase), which some investors view as a positive signal, but motivations are not disclosed.
• The second $0 disposed/derivative line may reflect an internal conversion, transfer, net settlement or administrative reporting detail; the Form 4 does not show an open‑market sale or cash proceeds tied to that line.